MiR-455-5p suppresses the progression of prostate cancer by targeting CCR5

25Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Accumulated evidence indicates that miR-455-5p functions as tumor suppressor in the progression of various cancers. However, the mechanism through which miR-455-5p influences the tumorigenesis of human prostate cancer (PCa) remains undetermined. In this study, reanalysis of data obtained from the Memorial Sloan Kettering Cancer Center showed that miR-455-5p can be used as biomarker for PCa diagnosis and predictor of poor prognosis. Functional assays indicated that miR-455-5p overexpression could suppress cellular proliferation, inhibit tumor growth, and trigger apoptosis by activating and cleaving caspase 3. We experimentally verified that miR-455-5p negatively regulated the C-C motif chemokine receptor 5 (CCR5). Overall, our data demonstrate that miR-455-5p suppressed PCa cellular proliferation and induced cell apoptosis by downregulating CCR5. Thus, miR-455-5p may be considered a new therapeutic strategy for PCa.

Cite

CITATION STYLE

APA

Xing, Q., Xie, H., Zhu, B., Sun, Z., & Huang, Y. (2019). MiR-455-5p suppresses the progression of prostate cancer by targeting CCR5. BioMed Research International, 2019. https://doi.org/10.1155/2019/6394784

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free